Adolor Corporation is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel prescription pain management products.

Adolor commenced operations in 1994 and was listed on Nasdaq GM as ADLR in 2000. Today, the company has approximately 115 employees working in areas that include discovery research, clinical development, manufacturing, business development, regulatory affairs, sales and marketing.

Pain is the most common symptom causing people to seek medical treatment in the United States. More than 25 million people in the United States each year experience chronic moderate-to-severe pain and pain causes more disability than cancer and heart disease combined.

The company was founded to capitalize on emerging proprietary development in cloned opioid receptors and continues today as a leader in the discovery and development of novel opioid receptor-targeted therapeutics. Additionally, Adolor's scientific staff is actively assessing other, non-opioid molecular targets. These research efforts work towards developing products that maintain or improve opioid-like pain relief while reducing or eliminating opioid side effects.

ENTEREG® (alvimopan), Adolor's first commercial product, is a peripherally-acting mu opioid receptor antagonist designed to block the negative effects of opioids, like morphine, on the gastrointestinal (GI) tract without interfering with central nervous system (CNS) mediated analgesia. ENTEREG, the first FDA approved therapy for postoperative ileus, was approved by the FDA on May 20, 2008 to accelerate upper and lower GI recovery following partial large or small bowel resection surgery with primary anastomosis. Entereg is available for short-term use in hospitals registered under the ENTEREG Access Support and Education (E.A.S.E.^TM) program.

Adolor has an exclusive worldwide collaboration with Pfizer Inc to develop and commercialize novel delta opioid receptor agonists for a wide range of inflammatory, neuropathic and acute pain conditions.

Adolor is also developing ADL7445 and ADL5945 to treat opioid bowel dysfunction (OBD), a condition that often results from chronic use of opioid analgesics to treat persistent pain conditions.

Adolor's other product candidates are in preclinical development for treating moderate-to-severe pain and other central nervous system conditions.

By applying its knowledge and expertise in pain management, along with ingenuity, Adolor Corporation is seeking to make a positive difference for patients, caregivers, and the medical community.